Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).

IF 3 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2024-05-03 DOI:10.1080/14796694.2024.2340960

Fabio Catalano, Matteo Brunelli, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Marco Maruzzo, Sara Merler, Francesca Vignani, Alessia Cavo, Davide Bimbatti, Michele Milella, Angelo Paolo Dei Tos, Marta Sbaraglia, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Michele Maffezzoli, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi

{"title":"Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study).","authors":"Fabio Catalano, Matteo Brunelli, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Marco Maruzzo, Sara Merler, Francesca Vignani, Alessia Cavo, Davide Bimbatti, Michele Milella, Angelo Paolo Dei Tos, Marta Sbaraglia, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Michele Maffezzoli, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi","doi":"10.1080/14796694.2024.2340960","DOIUrl":null,"url":null,"abstract":"Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months). Areas covered: The current study includes extensive immunohistochemical analysis of T-lineage markers (CD3, CD4, CD8, CD8/CD4 ratio), macrophages (CD68), ph-mTOR, CD15 and CD56 expression on tumor cells, and PD-L1 expression, on an increased sample size including 161 tumor samples (113 patients) compared with preliminary presented data. Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030). Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"1-19"},"PeriodicalIF":3.0000,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2024.2340960","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months). Areas covered: The current study includes extensive immunohistochemical analysis of T-lineage markers (CD3, CD4, CD8, CD8/CD4 ratio), macrophages (CD68), ph-mTOR, CD15 and CD56 expression on tumor cells, and PD-L1 expression, on an increased sample size including 161 tumor samples (113 patients) compared with preliminary presented data. Responders' tumor tissue (n = 90; 55.9%) was associated with lower CD4 expression (p = 0.014), higher CD56 expression (p = 0.046) and higher CD8/CD4 ratio (p = 0.030). Expert opinion/commentary: The present work suggests the regulatory role of a subpopulation of T cells on antitumor response and identifies CD56 as a putative biomarker of immunotherapy efficacy.

查看原文本刊更多论文

分析接受免疫疗法的晚期肾细胞癌患者的肿瘤微环境（Meet-URO 18 研究）。

研究简介Meet-URO 18研究是一项多中心研究，研究对象为二线及二线以上接受尼妥珠单抗治疗的转移性肾细胞癌患者，分为应答者（无进展生存期≥12个月）和非应答者（无进展生存期Area）：与初步数据相比，本次研究增加了样本量，包括 161 份肿瘤样本（113 位患者），对 T 线标志物（CD3、CD4、CD8、CD8/CD4 比值）、巨噬细胞（CD68）、肿瘤细胞上 ph-mTOR、CD15 和 CD56 的表达以及 PD-L1 的表达进行了广泛的免疫组化分析。应答者的肿瘤组织（n = 90；55.9%）与较低的 CD4 表达（p = 0.014）、较高的 CD56 表达（p = 0.046）和较高的 CD8/CD4 比值（p = 0.030）相关。专家意见/评论：本研究表明了T细胞亚群对抗肿瘤反应的调节作用，并将CD56确定为免疫疗法疗效的潜在生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.